An oncolytic vaccinia virus expressing CXCL11 combined with PD-L1 blockade significantly reduces tumor burden and improves survival in murine cancer models. 
and TME cells effectively combines with an anti-PD-L1 antibody to overcome these barriers.
Using the Western Reserve strain oncolytic vaccinia virus (v vDD), Liu et al. first demonstrated that infection with v vDD led to up-regulation of PD-L1 expression on several murine and human cancer cell lines. Mice bearing murine colon or ovarian cancer cell lines were then treated with control, anti-PD-L1 antibody, a CXCL11-expressing vvDD strain (VV) that enhances T cell infiltration and PD-L1 expression, and the combination of anti-PD-L1 antibody and VV. Combination therapy produced a dramatic antitumor effect and prolonged survival. Significant decreases in myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T cells were found in the TME of dual-treated tumors. Furthermore, tumorinfiltrating CD4 and CD8 effector T cells were increased, with decreased coinhibitory markers and increased activation markers, in the setting of combination therapy. Importantly, long-term surviving mice after dual therapy had significantly impaired tumor growth after tumor reimplantation compared with treatment naïve mice, demonstrating activation of systemic immunity. Depletion experiments showed that CD4 and CD8 T cells and IFN-γ were required for combination therapy efficacy.
This study showed that a PD-L1-inducing vaccinia virus strongly combined with PD-L1 blockade to reduce tumor burden and induce long-term survival in murine cancer models. This approach shows the feasibility of using OV to transform anti-PD-L1 resistant tumors into sensitive tumors by enhancing antitumor immunity in the TME and stimulating systemic antitumor immunity. Given the current clinical limitations of OV and checkpoint inhibition approaches, combining OV with PD-L1 blockade represents an exciting new cancer immunotherapy approach with potential broad applicability. 
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